LNDC Stock Forecast 2025-2026
Distance to LNDC Price Targets
LNDC Price Momentum
10 Quality Stocks Worth Considering Now
Researching Landec (LNDC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on LNDC and similar high-potential opportunities.
Latest LNDC Stock Price Targets & Analyst Predictions
Comprehensive analyst forecasts are currently unavailable for LNDC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LNDC Analyst Ratings
LNDC Price Target Range
Latest LNDC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LNDC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 7, 2022 | Barrington Research | Michael Petusky | Outperform | Maintains | $12.00 |
| Aug 11, 2022 | Barrington Research | Michael Petusky | Outperform | Upgrade | $14.00 |
| Jul 20, 2022 | Stephens & Co. | Overweight | Initiates | $0.00 | |
| Apr 6, 2022 | Barrington Research | Market Perform | Downgrade | $0.00 | |
| Oct 4, 2021 | Roth Capital | Gerry Sweeney | Buy | Maintains | $14.00 |
| Jul 30, 2021 | Roth Capital | Buy | Maintains | $15.00 | |
| Jun 2, 2021 | Barrington Research | Outperform | Upgrade | $0.00 | |
| Apr 9, 2021 | Roth Capital | Buy | Maintains | $12.00 | |
| Jan 6, 2020 | Barrington Research | Market Perform | Downgrade | $0.00 | |
| Sep 3, 2019 | Barrington Research | Outperform | Initiates | $0.00 | |
| Aug 23, 2019 | DA Davidson | Buy | Initiates | $0.00 | |
| Apr 8, 2019 | Roth Capital | Neutral | Downgrade | $0.00 | |
| Jul 8, 2016 | Wedbush | Neutral | Initiates | $0.00 | |
| Jun 7, 2016 | Maxim Group | Buy | Initiates | $0.00 | |
| Apr 2, 2015 | Imperial Capital | Outperform | Maintains | $18.00 | |
| Oct 9, 2014 | Feltl & Co. | Downgrade | $10.00 | ||
| Apr 14, 2014 | Northland Capital Markets | Outperform | Maintains | $14.00 | |
| Apr 14, 2014 | Northland Securities | Outperform | Maintains | $0.00 | |
| Apr 1, 2014 | Imperial Capital | Outperform | Initiates | $0.00 | |
| Mar 10, 2014 | Lake Street | Buy | Initiates | $0.00 |
Landec Corp (LNDC) Competitors
The following stocks are similar to Landec based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Landec Corp (LNDC) Financial Data
Landec Corp has a market capitalization of $182.60M with a P/E ratio of -1.9x. The company generates $185.79M in trailing twelve-month revenue with a 27.1% profit margin.
Revenue growth is -9.0% quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +164.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Landec Corp (LNDC) Business Model
About Landec Corp
Company Information
Landec Corp (LNDC) Latest News & Analysis
Latest News
Rosen Law Firm is investigating potential securities claims for Lifecore Biomedical shareholders due to allegations of misleading business information. Investors may be eligible for compensation with no upfront costs.
Allegations of misleading information from Lifecore Biomedical could lead to legal claims, impacting stock value and investor confidence. Potential compensation for affected shareholders adds urgency.
Rosen Law Firm is investigating potential securities claims for Lifecore Biomedical Inc. shareholders over allegations of misleading business information. Affected investors may seek compensation without upfront costs.
The investigation into Lifecore Biomedical for misleading information could lead to legal claims against the company, impacting its stock value and potentially providing compensation for affected shareholders.
Rosen Law Firm is investigating potential securities claims for Lifecore Biomedical Inc. (NASDAQ: LFCR) shareholders over allegations of misleading business information. Investors may seek compensation without upfront fees.
Allegations of misleading information from Lifecore Biomedical could lead to legal claims, impacting share value and investor confidence. Potential compensation may influence investor decisions.
Rosen Law Firm is investigating potential securities claims for Lifecore Biomedical Inc. shareholders due to allegations of misleading business information. Affected investors may qualify for compensation.
Allegations of misleading information by Lifecore Biomedical could lead to legal claims, impacting stock value and shareholder compensation options, which may affect investor sentiment and decisions.
Rosen Law Firm is investigating potential securities claims for Lifecore Biomedical (NASDAQ: LFCR), alleging misleading business information. Affected shareholders may seek compensation without upfront costs.
Allegations of misleading information can lead to legal claims, affecting Lifecore Biomedical's stock value and investor sentiment, potentially resulting in financial losses or compensation opportunities.
Landec Corporation (Nasdaq: LNDC) will have CEO Jim Hall and CFO John Morberg speak at the Stephens Annual Investment Conference in Nashville, TN.
The announcement of a fireside chat indicates Landec Corporation's transparency and engagement with investors, potentially impacting stock perception and investor confidence.
Frequently Asked Questions About LNDC Stock
What is Landec Corp's (LNDC) stock forecast for 2025?
Analyst forecasts for Landec Corp (LNDC) are not currently available. The stock is trading at $6.17.
Is LNDC stock a good investment in 2025?
According to current analyst ratings, LNDC has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.17. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LNDC stock?
Price predictions from Wall Street analysts for LNDC are not currently available. The stock is trading at $6.17.
What is Landec Corp's business model?
N/A
What is the highest forecasted price for LNDC Landec Corp?
Price targets from Wall Street analysts for LNDC are not currently available. The stock is trading at $6.17.
What is the lowest forecasted price for LNDC Landec Corp?
Price targets from Wall Street analysts for LNDC are not currently available. The stock is trading at $6.17.
What is the overall LNDC consensus from analysts for Landec Corp?
The overall analyst consensus for LNDC is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are LNDC stock price projections?
Stock price projections, including those for Landec Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.